��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2006, 32(1) 23-25 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	Ѫ��Ƥ��
	��
	��
	�Ų�Ƽ
	��̸�
	PubMed
	Article by ZHANG Cai-ping
	Article by CUI Pan-gen

��м��΢Ѫ��쳣��Ƽ��ƶԲ�

�Ų�Ƽ, ��̸�

�й�ҽѧ��ѧԺ��й�Э��ҽ�ƴ�ѧƤ��о��, �Ͼ�210042

ժҪ��

��м��Ĳ��Ҫ��Ƥϸ��쳣��ϸ��Tϸ��Ƥ��ͷ΢Ѫ��ŵ�,��Ƥ��ͷ��΢Ѫ��쳣��仯��̡��ع��΢Ѫ��쳣��ص��ؼ��俹Ѫ��Ʒ��״��Ǳ��ư�λ,��Ϊ��м��ٴ��Ƽ��ҩ�о�Ѱ��

�ؼ���� м�� Ѫ��Ƥ��

The Mechanisms of and Treatment Strategies for Abnormal Angiogenesis in Psoriasis

Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing 210042, China

Abstract:

The key pathophysiologic changes in psoriatic lesions include abnormal epidermal hyper-plasia, infiltration of inflammatory cells, activation of T lymphocytes and expansion as well as proliferation of the dermal microvasculature. And the abnormal proliferation of the microvasculature may trigger the pathogenic process. The pathogenesis of abnormal angiogenesis in psoriasis and anti-angiogenic therapy are reviewed, providing clues to the development of new therapeutic approaches to this disease.

Keywords: Psoriasis Vascular endothelial growth factors Therapy

�ո�� 2005-05-30 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Detmar M.The role of VEGF and thrombospondins in skin angiogenesis.J Dermatol Sci,2000,24(Suppl 1):S78-S84.
[2] Creamer D,Sullivan D,Bicknell R,et al.Angiogenesis in psoriasis.Angiogenesis,2002,5:231-236.
[3] Xia YP,Li B,Hylton D,et al.Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.Blood,2003,102:161-168.
[4] Young HS,Summers AM,Bhushan M,et al.Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.J Invest Dermatol,2004,122:209-215.
[5] Kim HJ,Kim TY.Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes,differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C.Br J Dermatol,2005,152:418.
[6] Kuroda K,Sapadin A,Shoji T,et al.Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis.J Invest Dermatol,2001,116:713-720.
[7] Voskas D,Jones N,Van Slyke P,et al.A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.Am J Pathol,2005,166:843-855.
[8] Li W,Tanaka K,Chiba Y,et al.Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs.Am J Physiol Heart Circ Physiol,2003,284:H23-30.
[9] Weiss JB,McLaughlin B.Endothelial cell stimulating angiogenesis factor.Int J Biochem Cell Biol,1998,30:423-427.
[10] Hotchkiss KA,Ashton AW,Schwartz EL.Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.J Biol Chem,2003,278:19272-19279.
[11] Longo R,Sarmiento R,Fanelli M,et al.Anti-angiogenic therapy:rationale,challenges and clinical studies.Angiogenesis,2002,5:237.
[12] Sauder DN,Dekoven J,Champagne P,et al.Neovastat (AE-941),an inhibitor of angiogenesis:Randomized phase I/II clinical trial results in patients with plaque psoriasis.J Am Acad Dermatol,2002,47:535-541.
[13] Beliveau R,Gingras D,Kruger EA,et al.The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.Clin Cancer Res,2002,8:1242-1250.
[14] Deng H,Yan CL,Hu Y,et al.Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro.Photodermatol Photoimmunol Photomed,2004,20:191-199.
[15] Diaz BV,Lenoir MC,Ladoux A,et al.Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids.J Biol Chem,2000,275:642-650.
[16] Hernandez GL,Volpert OV,Iniguez MA,et al.Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A:roles of the nuclear factor of activated T cells and cyclooxygenase 2.J Exp Med,2001,193:607-620.
[17] Fraser AD,van Kuijk AW,Westhovens R,et al.A randomised,double blind,placebo controlled,multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.Ann Rheum Dis,2005,64:859-864.
[18] Goedkoop AY,Kraan MC,Picavet DI,et al.Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy:a prospective single-centre study.Arthritis Res Ther,2004,6:R326-R334.
[19] Canete JD,Pablos JL,Sanmarti R,et al.Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.Arthritis Rheum,2004,50:1636-1641.